Application of metal fullerene monocrystal nanoparticles in preparation of specific tumor vascular disrupting agent

Abstract

The invention discloses an application of metal fullerene monocrystal nanoparticles in preparation of a tumor vascular disrupting agent. The monocrystal nanoparticles are water-soluble metal fullerene nanoparticles with the surface charged with negative electricity, and have the particle size range of 50-250 nm; the nanomaterial can absorb and convert outside world radiation energy into heat energy, and the volume is expanded sharply when a temperature reaches a phase transition point. During treatment, a tumor-carried living organism is injected and given with the metal fullerene monocrystal nanoparticles; the metal fullerene monocrystal nanoparticles reach a tumor part through blood circulation, and are stranded at tumor pores and defective parts; under the action of the outside world radiation energy, the metal fullerene monocrystal nanoparticles accumulate heat, the temperature rises, and the volume is expanded sharply when the temperature exceeds the phase transformation critical point, so that morphological structures or functions of tumor vascular endothelial cells are changed, and tumor vessels are interdicted so as to make the tumor cells starved to death.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of metal fullerene single crystal nanoparticles in tumor blood vessel blocking agents. Background technique [0002] In recent years, the morbidity and mortality of cancer have been on the rise. There are as many as 15 million new cancer patients in the world every year, which seriously threatens human health. The traditional three major tumor treatment methods, namely surgery, radiotherapy and chemotherapy, all have some limitations, causing cancer to become one of the leading causes of human death. In recent years, with the development of science and technology, some emerging physical, chemical and biological methods have emerged to treat tumors, such as hyperthermia, radiofrequency ablation therapy, photodynamic therapy and immunotherapy. [0003] In 1971, Folkman et al. proposed that the growth and metastasis of solid tumors depend on tumor angiogenesis, a...

AI Technical Summary

Problems solved by technology

However, the clinical trials of small molecule VDAs currently developed all reported cardiovascular adverse reactions such as hypertension, tachycardia, bradyarrhythmia, atrial fibrillation, myocardial infarction, etc. These adverse reactions limit their widespread clinical use.

Images